VAZCULEP (phenylephrine hydrochloride) by Aspiro Therapeutics is α-1 adrenergic receptor agonist. First approved in 2014.
Drug data last refreshed 6h ago · AI intelligence enriched 5d ago
VAZCULEP (phenylephrine HCl) is an intravenous α-1 adrenergic receptor agonist used to treat hypotension in acute care settings. It works by stimulating alpha-1 receptors on blood vessels to increase peripheral vasoconstriction and restore blood pressure. The drug is administered as an IV solution for rapid hemodynamic support in hospitalized patients.
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting a stable commercial environment with established hospital formulary presence and ongoing field engagement.
α-1 adrenergic receptor agonist.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study
Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers
Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)
Worked on VAZCULEP at Aspiro Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on VAZCULEP offers exposure to hospital-based commercialization, critical care relationships, and acute care market dynamics in a mature, stable product. Career progression will depend on formulary management, provider education, and field execution rather than pipeline advancement.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo